**WHAT IS CLAIMED IS:**

1. A compound of having the structure:




wherein

one of $R_1$ or $R_2$ is $-C(=O)OH$ and the other of $R_1$ or $R_2$ is $-C(=O)OR_{13}$ or $-C(=O)O\text{-alkyl-}R_{14}$,

wherein

$R_{13}$ is cycloalkyl, aryl or heteroaryl, and

$R_{14}$ is $CF_3$, cycloalkyl, cycloheteroalkyl, aryl or heteroaryl; and

$R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{10}$, $R_{11}$ and $R_{12}$ are each independently, H $-OR_{15}$ or halogen

wherein $R_{15}$ is H, $C_{1\text{-}10}$ alkyl, $C_{2\text{-}10}$ alkenyl, $C_{2\text{-}10}$ alkynyl, aryl, or heteroaryl,

wherein when one of $R_1$ or $R_2$ is $-C(=O)OH$ and $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{10}$, $R_{11}$ and $R_{12}$ are each H, then the other of $R_1$ or $R_2$ is other than $-C(=O)OR_{13}$ where $R_{13}$ is 1-naphthalene or 2-naphthalene or $-C(=O)O\text{-alkyl-}R_{14}$ where the alkyl is a branched $C_2$ alkyl and the $R_{14}$ is phenyl,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 having the structure:




wherein

one of $R_1$ or $R_2$ is –C(=O)OH and the other of $R_1$ or $R_2$ is $-C(=O)OR_{13}$ or $-C(=O)O\text{-alkyl-}R_{14}$,

wherein

$R_{13}$ is cycloalkyl, aryl or heteroaryl, and

$R_{14}$ is $CF_3$, cycloalkyl, aryl or heteroaryl; and

$R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{10}$, $R_{11}$ and $R_{12}$ are each independently, H $-OR_{15}$ or halogen

wherein $R_{15}$ is H, $C_{1\text{-}10}$ alkyl, $C_{2\text{-}10}$ alkenyl, $C_{2\text{-}10}$ alkynyl, aryl, or heteroaryl,

wherein when one of $R_1$ or $R_2$ is –C(=O)OH and $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{10}$, $R_{11}$ and $R_{12}$ are each H, then the other of $R_1$ or $R_2$ is other than $-C(=O)OR_{13}$ where $R_{13}$ is 1-naphthalene or 2-naphthalene, or $-C(=O)O\text{-alkyl-}R_{14}$ where the alkyl is a branched $C_2$ alkyl and the $R_{14}$ is phenyl,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 or 2, wherein when one of $R_1$ or $R_2$ is –C(=O)OH and $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{10}$, $R_{11}$ and $R_{12}$ are each H, then the other of $R_1$ or $R_2$ is other than $-C(=O)OR_{13}$ where $R_{13}$ is tolyl, 1-

naphthalene or 2-naphthalene, or –C(=O)O-alkyl-$R_{14}$ where the alkyl is a branched $C_2$ alkyl and the $R_{14}$ is phenyl.

4. The compound of claim 1 or 2, wherein when one of $R_1$ or $R_2$ is –C(=O)OH and the other of $R_1$ or $R_2$ is –C(=O)$OR_{13}$ where $R_{13}$ is 1-naphthalene or 2-naphthalene, then one of $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{10}$, $R_{11}$ and $R_{12}$ is other than –H; or
wherein when one of $R_1$ or $R_2$ is –C(=O)OH and the other of $R_1$ or $R_2$ is –C(=O)$OR_{13}$ where $R_{13}$ is 1-naphthalene or 2-naphthalene, then two of $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{10}$, $R_{11}$ and $R_{12}$ is other than –H; or
herein when one of $R_1$ or $R_2$ is –C(=O)OH and the other of $R_1$ or $R_2$ is –C(=O)$OR_{13}$ where $R_{13}$ is 1-naphthalene or 2-naphthalene, then four of $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{10}$, $R_{11}$ and $R_{12}$ is other than –H.

5. The compound of any one of claims 1-4,
wherein
one of $R_1$ or $R_2$ is –C(=O)$OR_{13}$,
wherein $R_{13}$ is cycloalkyl, aryl or heteroaryl; and
the other of $R_1$ or $R_2$ is –C(=O)OH.

6. The compound of any one of claims 1-4,
wherein
one of $R_1$ or $R_2$ is –C(=O)O-alkyl-$R_{14}$,
wherein $R_{14}$ is $CF_3$, cycloalkyl, aryl or heteroaryl; and
the other of $R_1$ or $R_2$ is –C(=O)OH.

7. The compound of any one of claims 5 or 6, wherein the aryl or heteroaryl is a substituted aryl or heteroaryl, wherein the aryl or heteroaryl is substituted with a halogen, -OH, heteroaryl, $C_2$-$C_6$ alkynyl, –O(alkyl), amide, aryl or hydroxyaryl.

8. The compound of claim 7, wherein the aryl is substituted with a F, Cl, Br, -OH, I, -NHC(O)$CH_3$, triazolyl, $C_2$ alkynyl, phenyl, *o*-hydroxyphenyl or –$OCH_3$.

9. The compound of claim 7, wherein the heteroaryl is substituted with a F, Cl, Br, -OH, I, -NHC(O)$CH_3$, triazolyl, $C_2$ alkynyl, phenyl, *o*-hydroxyphenyl or $-OCH_3$.

10. The compound of any one of claims 5 or 6, wherein the cycloalkyl is a substituted cycloalkyl, wherein the cycloalkyl is substituted with a phenyl or a fused benzo group.

11. The compound of any one of claims 1-4,

wherein

one of $R_1$ or $R_2$ is


,

,

,

,

,

,

or

, and

the other of $R_1$ or $R_2$ is –C(=O)OH; or

wherein

one of $R_1$ or $R_2$ is , , , ,  or , and

the other of $R_1$ or $R_2$ is –C(=O)OH; or

wherein

one of $R_1$ or $R_2$ is , , , , , , ,  or , and

the other of $R_1$ or $R_2$ is –C(=O)OH.

12. The compound of any one of claims 1-11, wherein $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{10}$, $R_{11}$ and $R_{12}$ are each independently, -H, $-NO_2$, halogen or $-OR_{15}$,

wherein $R_{15}$ is -H or $C_{1-10}$ alkyl.

13. The compound of any one of claims 1-11, wherein one of $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{10}$, $R_{11}$ and $R_{12}$ is other than –H.

14. The compound of any one of claims 1-11, wherein two of $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{10}$, $R_{11}$ and $R_{12}$ are other than –H; or wherein four of $R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{10}$, $R_{11}$ and $R_{12}$ are other than –H.

15. The compound of any one of claims 1-11, wherein $R_3$, $R_4$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{11}$ and $R_{12}$ are each –H; and $R_5$ and $R_{10}$ are each halogen or $-OR_{15}$,

wherein $R_{15}$ is -H, $C_{1-10}$ alkyl, $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, aryl, or heteroaryl; or

wherein $R_4$, $R_5$, $R_6$, $R_9$, $R_{10}$ and $R_{11}$ are each –H; $R_3$ and $R_{12}$ are each –H, halogen or $-OR_{15;}$ and $R_7$ and $R_8$ are each halogen or $-OR_{15}$,

wherein $R_{15}$ is -H, $C_{1-10}$ alkyl, $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, aryl, or heteroaryl; or

wherein $R_3$, $R_4$, $R_7$, $R_8$, $R_9$ and $R_{12}$ are each –H; and $R_5$, $R_6$, $R_{10}$ and $R_{11}$ are each halogen or $-OR_{15}$,

wherein $R_{15}$ is -H, $C_{1-10}$ alkyl, $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, aryl, or heteroaryl.

16. The compound of any one of claims 1-11, wherein $R_3$, $R_4$, $R_5$, $R_6$, $R_8$, $R_9$, $R_{10}$ and $R_{1a}$ are each –H; and $R_7$ and $R_{12}$ are each $NO_2$.

17. The compound of claim 1,

wherein

one of $R_1$ or $R_2$ is –C(=O)OH and the other of $R_1$ or $R_2$ is $-C(=O)OR_{13}$ or $-C(=O)O\text{-alkyl-}R_{14}$,

wherein

$R_{13}$ is cycloalkyl or aryl, and

$R_{14}$ is $CF_3$, cycloheteroalkyl or aryl; and

$R_3$, $R_4$, $R_5$, $R_6$, $R_7$, $R_8$, $R_9$, $R_{10}$, $R_{11}$ and $R_{12}$ are each independently, H or $-OR_{15}$,

wherein $R_{15}$ is H or $C_{1-10}$ alkyl.

18. The compound of claim 1 having the structure:



,


,


,


,


,


,


,


,


,


,


,


,



















,


,


,


,


,


,


or


,

or an enantiomer or racemate thereof;

or a pharmaceutically acceptable salt thereof.

19. The compound of any one of claims 1-18, wherein the compound is the (S,S) enantiomer.

20. The compound of any one of claims 1-18, wherein the compound is the (R,R) enantiomer.

21. A pharmaceutical composition comprising the compound of any one of claims 1-20 and a pharmaceutically acceptable carrier.

22. A method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with the compound of any one of—claims 1-20.

23. The method of claim 22, wherein the compound inhibits binding of an FABP ligand to the FABP.

24. The method of claim 23, wherein the FABP ligand is an endocannabinoid ligand, anandamide (AEA) or 2-arachidonoylglycerol (2-AG).

25. The composition of claim 21, wherein the composition comprises a mixture of enantiomers enriched in (S,S) enantiomer or a mixture of enantiomers enriched in (R,R) enantiomer.